contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aegirbio-uk-ltd-and-undisclosed-partner-sign-loi-to-develop-innovative-digital-diagnostic-product

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Subgen AI develops both infrastructure and proprietary agent-centric AI-as-a-Service software, branded Serenity Star. The company's solutions are designed to scale and accelerate the implementation of AI in organizations. Subgen AI delivers services to clients in sectors such as healthcare, energy, legal and human resources. Subgen AI operates in Europe, Latin America and the United States.

Subgen AI

Aegirbio UK Ltd, a subsidiary of Magnasense AB, has signed a Letter of Intent (LOI) with an undisclosed partner to jointly develop and supply a next-generation saliva based digital diagnostic...

<div class="mfn-preamble"><p><strong>Aegirbio UK Ltd, a subsidiary of Magnasense AB, has signed a Letter of Intent (LOI) with an undisclosed partner to jointly develop and supply a next-generation saliva based digital diagnostic product for professional use, aimed at monitoring health related problems. The partner has deliberately chosen not to take a leading role in the development process and does not intend to publicly disclose strategic details, to avoid offering insights that could benefit competitors.</strong></p></div><div class="mfn-body"><p>This collaboration brings together Aegirbio’s expertise in advanced diagnostics and digital health technology with the partner’s strong market position and regulatory know-how.</p><p>Under the planned agreement, Aegirbio UK Ltd will lead the design, development, and validation of a cutting-edge diagnostic system—including a reusable magnetic reader, single-use cartridge, sample collection tools, and a cloud-connected software platform.</p><p>Following successful development, Aegirbio UK Ltd will also assume responsibility for manufacturing through a subcontracting model. The partner will provide milestone-based development funding and overseeing regulatory approvals and import licensing.</p><p>The LOI outlines both parties’ intention to finalize a formal agreement in 2025 and includes key provisions regarding intellectual property rights, exclusivity, technology transfer, and long-term business continuity.</p><p><strong>Quotes:</strong><br>"<em>This LOI marks a significant milestone for Aegirbio UK as we expand our presence in the professional diagnostics space</em>," said Marco Witteveen, CEO of Aegirbio UK Ltd. "<em>We are proud to collaborate with a trusted industry leader to bring innovative digital tools to market</em>."</p><p><strong>About Aegirbio UK Ltd</strong><br>Aegirbio UK Ltd is a subsidiary of Magnasense AB, a Swedish diagnostics company specializing in advanced point-of-care solutions and digital health platforms.</p></div><div class="mfn-footer mfn-contacts mfn-e503b60338ed"><p><strong class="mfn-heading-1">For additional information, please contact:</strong><br>Marco Witteveen, CEO, Magnasense AB<br>Email: <a rel="noopener" href="mailto:ir@aegirbio.com">ir@magnasense.com</a><br>The Company’s Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se</p></div><div class="mfn-footer mfn-about mfn-8c31e8f3e677"><p><strong class="mfn-heading-1">About Magnasense AB</strong><br>Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/fe44f6cf-8996-4751-8265-92f4699b5b81/aegirbio-uk-ltd-and-undisclosed-partner-sign-loi-to-develop-innovative-digital-diagnostic-product.pdf" class="mfn-generated mfn-primary">Aegirbio UK Ltd and Undisclosed Partner Sign LOI to Develop Innovative Digital Diagnostic Product</a></p></div>

Aegirbio UK Ltd and Undisclosed Partner Sign LOI to Develop Innovative Digital Diagnostic Product